Impaired urinary flow in male patients, benign prostate hyperplasia and primary approaches to the treatment of lower urinary tract symptoms


DOI: https://dx.doi.org/10.18565/therapy.2020.8.192-198

Ergakov D.V., Martov A.G.

1) A.I. Burnazyan State Scientific Federal Medical Biophysical Center of FMBA of Russia, Moscow; 2) D.D. Pletnev City Clinical Hospital of the Moscow Public Healthcare Department
Impaired urination in male patients is an important socio-medical problem that grows with age. Insufficient availability of specialized urological care is the reason for the frequent appeal of that patient category to therapists and general practitioners. This article provides actual information on the prevalence of urination disorders in males, the main causes of their occurrence, main symptoms, pathologies that are most often included in the range of differential diagnostic search, and priority methods of initial therapy. The data on the efficacy and tolerability of the uroselective α1-adrenergic blocker tamsulosin at a dose of 0.4 mg/day (original medicine Omnic®) and its modified-release form (Omnic® OCAS) as a first-line drug in the treatment of urinary disorders are considered separately.
Keywords: Omnic® OCAS, Omnic®, lower urinary tract symptoms, tamsulosin, benign prostatic hyperplasia
Read entire article

Literature


  1. Welk B., McArthur E., Fraser L.-A. et al. The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist: a population based cohort study. BMJ. 2015; 351: h5398. doi: 10.1136/bmj.h5398.

  2. Gravas S., Cornu J.N., Gacci M. et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). European Association of Urology. 2019. URL: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-the-Management-of-Non-Neurogenic-Male-LUTS-2019.pdf (date of access – 01.12.2020).

  3. Irwin D.E., Kopp Z.S., Agatep B. et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011; 108(7): 1132–38. doi: 10.1111/j.1464-410X.2010.09993.x.

  4. Лоран О.Б., Серегин А.А. Эффективность и безопасность применения препарата Омник Окас для пациентов с симптомами нижних мочевыводящих путей на фоне доброкачественной гиперплазии простаты в рутинной клинической практике в Российской Федерации (проспективная многоцентровая наблюдательная программа). Урология. 2018; 2: 68–74. [Loran O.B., Seregin A.A. The effectiveness and safety of Omnik Ocas in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia in the routine clinical practice in the Russian Federation (prospective multi-center observing program). Urologiya. 2018; 2: 68–74 (In Russ.)]. doi: 10.18565/urology.2018.2.68-74.

  5. Cindolo L., Pirozzi L., Fanizza C. et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2015; 68(3): 418–25. doi: 10.1016/j.eururo.2014.11.006.

  6. Gacci M., Ficarra V., Sebastianelli A. et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014; 11(6): 1554–66. doi: 10.1111/jsm.12525.

  7. Sakalis V.I., Karavitakis M., Bedretdinova D. et al. Medical treatment of nocturia in men with lower urinary tract symptoms: systematic review by the European Association of Urology guidelines panel for male lower urinary tract symptoms. Eur Urol. 2017; 72(5): 757–69. doi: 10.1016/j.eururo.2017.06.010.

  8. Biaggioni I. Orthostatic hypotension in the hypertensive patient. Am J Hypertens. 2018; 31(12): 1255–59. doi: 10.1093/ajh/hpy089.


About the Autors

Dmitry V. Ergakov, PhD., associate professor of the Department of urology and andrology of A.I. Burnazyan State Scientific Federal Medical Biophysical Center of FMBA of Russia, doctor of the 2nd urological Department of D.D. Pletnev City Clinical Hospital of the Moscow Public Healthcare Department. Address: 123098, Moscow, 23 Marshala Novikova Str. E-mail: dergakov@mail.ru
Alexey G. Martov, MD, professor, head of the Department of urology and andrology of A.I. Burnazyan State Scientific Federal Medical Biophysical Center of FMBA of Russia, head of the 2nd urological Department of D.D. Pletnev City Clinical Hospital of the Moscow Public Healthcare Department. Address: 123098, Moscow, 23 Marshala Novikova Str. E-mail: martovalex@mail.ru


Similar Articles

Back to Content

Бионика Медиа